KR20220087461A - Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도 - Google Patents

Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20220087461A
KR20220087461A KR1020227014893A KR20227014893A KR20220087461A KR 20220087461 A KR20220087461 A KR 20220087461A KR 1020227014893 A KR1020227014893 A KR 1020227014893A KR 20227014893 A KR20227014893 A KR 20227014893A KR 20220087461 A KR20220087461 A KR 20220087461A
Authority
KR
South Korea
Prior art keywords
phosphate
crystalline form
xrpd pattern
polymorph
pattern
Prior art date
Application number
KR1020227014893A
Other languages
English (en)
Korean (ko)
Inventor
매튜 톡즈코
제드 허브스
유시 닝
젱 제인 리
윤리앙 헤
시앙레이 리우
Original Assignee
뉴로사이클 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로사이클 테라퓨틱스, 인크. filed Critical 뉴로사이클 테라퓨틱스, 인크.
Publication of KR20220087461A publication Critical patent/KR20220087461A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR1020227014893A 2019-10-22 2020-10-22 Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도 KR20220087461A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924276P 2019-10-22 2019-10-22
US62/924,276 2019-10-22
PCT/US2020/056750 WO2021081147A1 (en) 2019-10-22 2020-10-22 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
KR20220087461A true KR20220087461A (ko) 2022-06-24

Family

ID=75619360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014893A KR20220087461A (ko) 2019-10-22 2020-10-22 Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도

Country Status (14)

Country Link
US (1) US20230017378A1 (zh)
EP (1) EP4048672A4 (zh)
JP (1) JP2022553718A (zh)
KR (1) KR20220087461A (zh)
CN (1) CN114981266A (zh)
AU (1) AU2020371635A1 (zh)
BR (1) BR112022007522A2 (zh)
CA (1) CA3154222A1 (zh)
CL (1) CL2022000980A1 (zh)
IL (1) IL292340A (zh)
MX (1) MX2022004642A (zh)
TW (1) TW202128697A (zh)
UY (1) UY38930A (zh)
WO (1) WO2021081147A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936608B2 (en) * 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
JP6491679B2 (ja) * 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
BR112020021104A2 (pt) * 2018-04-18 2021-02-23 Neurocycle Therapeutics, Inc compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos
JP2022554159A (ja) * 2019-10-23 2022-12-28 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療

Also Published As

Publication number Publication date
WO2021081147A1 (en) 2021-04-29
EP4048672A4 (en) 2023-11-15
CL2022000980A1 (es) 2023-01-20
UY38930A (es) 2021-05-31
CN114981266A (zh) 2022-08-30
US20230017378A1 (en) 2023-01-19
TW202128697A (zh) 2021-08-01
MX2022004642A (es) 2022-05-10
IL292340A (en) 2022-06-01
EP4048672A1 (en) 2022-08-31
JP2022553718A (ja) 2022-12-26
BR112022007522A2 (pt) 2022-07-12
CA3154222A1 (en) 2021-04-29
AU2020371635A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7449272B2 (ja) Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
JP7352841B2 (ja) ３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
CA2852771C (en) Process for preparing quinoline derivatives
JP7199739B2 (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
JP2017002048A (ja) ピリミド［６，１−ａ］イソキノリン−４−オン化合物の結晶形態
CN115667261A (zh) 吉泊达星的结晶形式
CA3146130A1 (en) Formulations of rbp4 inhibitors and methods of use
JP2024056724A (ja) ムスカリン性アセチルコリン受容体アゴニストの結晶性多形
KR20220087461A (ko) Gabaa 포지티브 알로스테릭 조정제 화합물, 그의 제조 방법 및 용도
TW202309032A (zh) 帽柱木鹼及３－氘帽柱木鹼之鹽類及多形體
EP4169915A1 (en) Crystalline form of compound
WO2023197934A1 (zh) 阿片受体拮抗剂缀合物的固体盐型、晶型及其制备方法、组合物和用途
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
JP2023116756A (ja) 置換キノキサリン型架橋ピペリジン化合物の多形形態
WO2023137035A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
JP6038788B6 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン化合物の結晶形態
EP4373579A1 (en) Ulodesine salt
CA2750010A1 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
EP2154137A1 (en) Crystalline form of moxifloxacin base